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Abstract
Objectives: To determine whether there is a relationship between the total BP dose administered and the variations 
in serum CTX concentration.
Study design: The study included 50 patients requiring dental implant surgery and treated with oral BPs, seen in 
an Oral Surgery and Implantology Unit between January 2007 and June 2009. The patients were divided into two 
groups: those in which the medication was not suspended before obtaining the laboratory test sample, and those 
patients referred from other dental clinics in which BPs was suspended before reporting to our Unit. The total 
drug dosage administered and the total dose per kilogram body weight were evaluated for comparison with serum 
CTX. The data obtained were correlated to the osteonecrosis risk table developed by Marx et al. in 2007.
Results: There were no significant differences between the two groups in relation to the total administered dose 
and the dose in mg/kg b.w. Likewise, in both groups no relationship was observed between the serum CTX value 
and the total administered dose or the dose in mg/kg b.w. No differences were found between the two patient 
groups regarding chemical osteonecrosis risk based on the criteria of Marx et al.
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Conclusions: No relationship was observed between the oral BP dose administered (total dose or expressed in mg/kg 
b.w.) and serum CTX concentration, and suspension of the medication did not influence the serum CTX levels.
Key words: Serum CTX, osteonecrosis, oral bisphosphonates.
Introduction
Serum carboxyterminal cross-linking telopeptide of 
type I collagen (CTX) is a marker of osteoclast func-
tion. A number of authors have correlated serum CTX 
to the administration of bisphosphonates (BPs), such as 
Greenspan et al. (1), Chailurkit et al. (2) and Brown et al. 
(3), who reported a decrease in serum CTX following 
the administration of BPs. However, other authors such 
as Peris et al. (4) and Kunchur et al. (5) have observed 
no such relationship. 
Marx et al. (6) reported a relationship between low 
serum CTX values and an increased incidence of os-
teonecrosis of the jaws (ONJ). These authors developed 
tables designed to establish the relative risk of develop-
ing ONJ as a function of the serum CTX levels. In this 
context, values under 100 pg/ml represented high risk, 
values between 100-150 pg/ml represented moderate 
risk, and concentrations of over 150 pg/ml were taken 
to indicate minimal risk. The investigators estimated 
that serum CTX increases between 25.9 - 26.4 pg/ml for 
each month without the administration of BPs. 
The present study, involving a group of patients treated with 
BPs via the oral route, was designed to determine whether 
there is a relationship between the BP dose administered 
and the variations in serum CTX concentration.
Material and Methods
-Patients
The study included 50 patients requiring dental implant 
surgery and treated with oral BPs, seen in the Oral 
Surgery and Implantology Unit of a University Dental 
Clinic between January 2007 and June 2009. 
A case history was compiled on each patient, including 
age, gender, weight, disease antecedents of interest, and 
usual medication (drug, dose and duration of treatment). 
The specialists prescribing BP treatment were consult-
ed to determine whether it would be possible to switch 
to some other type of medication.
In this context, two groups were established: group A 
(patients directly visiting our Unit and who continued 
to take BPs) and group B (patients who stopped taking 
BPs before collecting the laboratory test sample). 
The patients in group B were subjects referred from pri-
vate dental clinics to our Unit for treatment. Some of the 
dental surgeons referring the patients had already con-
sulted the specialist about the possibility of suspending 
BP treatment, replacing it with some other type of drug. 
The rest of the referred patients stopped taking BPs on 
their own accord after being explained about the risk 
of complications, or because the prescribing specialist 
decided that BP treatment had concluded. 
-Laboratory tests
The total drug dosage administered and the total dose per 
kilogram body weight were assessed for the study of serum 
CTX. The patients reported to the laboratory under fasting 
conditions. The data obtained were correlated to the os-
teonecrosis risk table developed by Marx et al. in 2007.
-Statistical analysis
A descriptive analysis was made in both patient groups 
of gender, age, body weight, medication, total dosage 
and dose expressed as mg/kg body weight, data accura-
cy and serum CTX concentration. Sample distribution 
was assessed, and in those cases where a non-normal 
distribution was suspected, we applied the correspond-
ing nonparametric tests, with the same results. The sta-
tistical analysis was performed using the SPSS version 
15.0 statistical package for Microsoft Windows (SPSS 
Inc., Chicago, IL, USA).
Results
Two patients refused laboratory testing and were ex-
cluded from the study. A total of 50 patients were evalu-
ated: one male and 49 females. The mean patient age 
was 63.8 years (range 51-77). The mean body weight 
was 60.6 kg (range 44-79). Patient distribution accord-
ing to the administered BP is shown in table 1.
Table 1. Patient distribution according to the drug prescribed.
Alendronate 
70 mg/wk
Risedronate 
35 mg/wk
Ibandronate 
35 mg/wk
Ibandronate 
150 mg/mo
Alendronate (70 mg/wk) 
+Ibandronate (35 mg/wk)
Alendronate (70 mg/wk) 
+Risedronate (35 mg/wk)
29 14 1 2 2 2
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Eighty percent of the patients knew the exact timing 
of their medication (with a report from the prescribing 
physician, stating the exact date on which treatment was 
started), while 20% were only able to offer an estimate 
(without the corresponding report from the prescribing 
physician). The mean duration of BP therapy was 42 
months (range 4-132). As regards patient distribution, 
46% belonged to group A and 54% to group B. In the 
latter group, the mean time without BP treatment was 
5.8 months (range 1-12). 
The serum CTX concentration ranged between 60-880 pg/
ml. On classifying the laboratory test data according to the 
ranges described by Marx et al. (6) for assessing the risk of 
bone necrosis, 22% were seen to present no risk (≥ 300 pg/
ml), 44% minimum risk (150-299 pg/ml), 22% moderate 
risk (100-150 pg/ml) and 12% high risk (˂100 pg/ml).
There were no statistically significant differences be-
tween the two groups (p>0.005) regarding the total ad-
ministered dose (F=2.095), the total dose per kg body 
weight (F=0.778), the serum CTX values (F=1.697) 
(Fig. 1), or osteonecrosis risk (χ2=2.972) (according to 
the criteria of Marx et al. 2007).
Fig. 1. Relationship between the two study groups in reference to 
serum CTX concentration.
Fig. 2. Dispersion chart showing the relationship between the ad-
ministered bisphosphonate doses and serum CTX concentration in 
the two study groups.
The dispersion chart in figures 2, 3 shows that no rela-
tionship was found between the total drug dosage ad-
ministered or the total dose per kilogram body weight 
and the serum CTX concentration.
Fig. 3. Dispersion chart showing the relationship between the ad-
ministered bisphosphonate doses and serum CTX concentration in 
the two study groups.
Discussion
A number of studies have related treatment with oral 
bisphosphonates (BPs) to reductions in bone resorption 
markers. Chailurkit et al. (2) administered 10 mg of al-
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endronate a day to 70 patients, and recorded a signifi-
cant reduction in serum CTX after both 6 months and 
one year of treatment. Brown et al. (3), in 125 patients 
with bone metastases, reported a significant reduction 
in serum CTX at daily doses of ≥ 1600 mg of clodro-
nate via the oral route, after 6 months of treatment. In 
the present study, the mean duration of treatment was 
42 months, which is significantly longer than the dura-
tion of therapy in the studies of Chailurkit et al. (2) and 
Brown et al. (3). 
Peris et al. (4), in patients with Paget’s disease, recorded 
no significant decrease in serum CTX following treat-
ment with BPs. In our series we likewise found no rela-
tionship between the total drug dosage administered or 
the total dose per kilogram body weight and the serum 
CTX concentration.
Marx et al. (6), in patients with bone necrosis second-
ary to BP treatment, found a relationship between os-
teonecrosis risk and serum CTX. In contrast to the 
results obtained by Marx et al. (6), in our study there 
was no relationship between serum CTX and the risk of 
bone necrosis. 
In turn, Kunchur et al. (5) evaluated the efficacy of se-
rum CTX testing in assessing the risk of osteonecrosis in 
348 patients treated with oral BPs. According to these au-
thors, the mentioned serum test is unable to predict bone 
necrosis risk, in coincidence with our own findings.
A number of studies involving patients receiving BPs 
via the intravenous route likewise reported no relation-
ship between serum CTX and the risk of bone necrosis. 
This is the case for example of the articles published by 
Lehrer et al. (7) and Bagán et al. (8), who recorded no 
correlation between serum CTX and exposed areas of 
bone necrosis.
On the basis of the total drug dose, the duration of treat-
ment, patient body weight and the time of treatment sus-
pension before the study, we conclude that it is doubtful 
whether the serum CTX test is of help in determining 
osteonecrosis risk in patients treated with oral bisphos-
phonates. Nevertheless, studies involving larger sample 
sizes are needed to confirm these findings.
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